A prospective pilot trial from another team revealed encouraging results when targeting the CnF in a patient with PD and levodopa-resistant freezing of gait (improved “timed up and go” test, increased stride length and velocity, longer swing phase duration; Chang, Cajigas, and others 2021). Here, NPHS1 is linked to Parkinson disease.